In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In one of his latest appearances on CNBC's Squawk on the Street, Jim Cramer ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $996.00. The company’s shares closed yesterday ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

Nearly 200 Eli Lilly and Co. employees from the Lebanon site under construction volunteered to distribute 75,000 diapers to eight Boone County non-profit organizations. The community service ...

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, even if there were reasons for ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $997.00. Discover outperforming stocks and ...

The company also shared 2025 revenue guidance, anticipating sales will be between $58.0 billion and $61.0 billion. For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

(Bloomberg) -- Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second ...